Status:
UNKNOWN
Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer
Lead Sponsor:
Joong Bae Ahn
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
19+ years
Brief Summary
* Registry * Multicenter, prospective observational study * Observe adverse events and efficacy in recruited patients for 3 years under real world settings.
Eligibility Criteria
Inclusion
- Adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive Bevacizumab or Cetuximab in combination with FOLFIRI regimen as first-line treatment
- Patients who will receive irinotecan, a component of FOLFIRI regimen, using Camtop Injection®
Exclusion
- 1\) Patients with conditions in which any study drug is contraindicated per the respective approved label.
Key Trial Info
Start Date :
November 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT03286738
Start Date
November 1 2015
End Date
December 1 2021
Last Update
April 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University Health System, Severance Hospital
Seoul, South Korea, 03722